Krsnaa Diagnostics Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Krsnaa Diagnostics Ltd trades at ₹550, in a downtrend and 38 weeks into that stage. That is −10.0% against its own 200-day average. It sits at 8% of a 52-week range of ₹527 to ₹825. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.

Today the stock is in a downtrend — week 38 of stage 4, confirmed. At ₹550 it trades −10.0% versus its 200-day average and sits at 8% of its 52-week range (₹527–₹825).

Against the market, two honest reads. Cumulative: over the last 5.1 years the stock moved −41% while the NIFTY 500 moved +62% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Krsnaa Diagnostics Ltd trades at 18.3× P/E, near the bottom of its own range — cheaper only 7% of the time. Its long-run median P/E is 28.9×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 18.3× is near the bottom of its own range — cheaper only 7% of the time, against a long-run median of 28.9× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +30.1% against a −33.5% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the −6.9%/yr price move, ~+14.7%/yr came from earnings growth and ~−21.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 13 June 2026 price, Krsnaa Diagnostics Ltd was paying for profit growth of about 9.8% a year. Today the market pays 18.3× P/E, the 7th percentile of its own 4-year range.

What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is the whole of what a buyer is backing.

How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Krsnaa Diagnostics Ltd reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 13.0% is below the 15% bar this page requires to call it Consistent. The read is built from 8 quarters across 4 curves, on partial evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

36.5/100 — rank 9 of 9 in Diagnostics · 81% evidence confidence

Krsnaa Diagnostics Ltd scores 36.5 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 9. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.

The four contributions add to the total exactly: 10.7 + 8.3 + 14.5 + 3 = 36.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Krsnaa Diagnostics Ltd reported ₹236 Cr of revenue in the Jun 26 quarter, +22.3% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 34.8% a year. The last full year, FY26, came in at ₹773 Cr. The last four reported quarters add to ₹816 Cr.

FY26 revenue came in at ₹773 Cr (+7.8% on the year), capping 10 years at 34.8% compound. The latest quarter (Jun 26) printed ₹236 Cr, +22.3% year on year — the 11th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +10.1% growth against the decade's 34.8% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +10.3% over the last 4 quarters against +12.1%/yr over the last 8 — stabilising; TTM profit +21.0% vs +27.8%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Krsnaa Diagnostics Ltd's operating margin is 25.0% in the Jun 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged −57.0% to 41.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 25.0%, −2.0 pp against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged −57.0%–41.0%.

🚨 Why the margin moved: operating margin went −2.0 pp year on year while gross margin went +3.3 pp — the loss came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Krsnaa Diagnostics Ltd earned ₹17.0 Cr of net profit in the Jun 26 quarter, −19.0% year on year. Full-year FY26 profit was ₹101 Cr. That is 7.2% of the quarter's revenue. The same quarter a year earlier earned ₹21.0 Cr.

Jun 26 profit was ₹17.0 Cr, −19.0% year on year. On the full year, FY26 printed ₹101 Cr (+29.5%).

🚨 Why profit moved: revenue contributed +22.3% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +20.0% vs revenue +10.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 108% of Krsnaa Diagnostics Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹143 Cr of operating cash against ₹101 Cr of profit. After ₹281 Cr of capital spending, ₹−138 Cr was left as free cash.

FY26: operating cash of ₹143 Cr against reported profit of ₹101 Cr, leaving free cash of ₹−138 Cr after ₹281 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 108% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 108%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.

Router verdict: the bigger cash user is investment — capital spending ran 2.5× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Krsnaa Diagnostics Ltd's cash conversion cycle runs 65 days in FY26, down from 69 days in FY21. Capital spending ran ₹621 Cr over the last 3 years. At FY26 sales of ₹773 Cr each day of that cycle holds about ₹2.1 Cr, so roughly ₹138 Cr sits inside the business at any moment.

FY26: debtors at 140 days, inventory at 54 days — roughly 1.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 65 days, tighter than FY21's 69.

The full loop: cash goes out to suppliers and production on day 0; stock waits 54 days to sell; customers pay about 140 days after that; and suppliers themselves are paid at 129 days — netting out to the 65-day cycle.

In money terms: at FY26 sales of ₹773 Cr, each day of the cycle holds about ₹2.1 Cr — so the 65-day loop keeps roughly ₹138 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹621 Cr over the last 3 fiscal years against ₹253 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹208 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Krsnaa Diagnostics Ltd earns a ROCE of 13% in FY26. That is up from a trough of −65% in FY20. Return on invested capital clears the cost of that capital by −2.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 13.1% net margin on 0.42× asset turns.

FY26 ROCE is 13%, recovered from a FY20 trough of −65% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 13.1% net margin × 0.42× asset turns × 1.86× balance-sheet leverage ≈ 10.2% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 9.9% − 12.0% = a −2.1 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Krsnaa Diagnostics Ltd carries total debt of ₹534 Cr against shareholder equity of ₹980 Cr as of Mar 26, a debt-to-equity of 0.54. On the annual view that ratio went from 0.06 in FY22 to 0.54 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹534 Cr against shareholder equity of ₹980 Cr — a debt-to-equity of 0.54. On the annual view, debt-to-equity went from 0.06 (FY22) to 0.54 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 1.0 points of Krsnaa Diagnostics Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 4.3% of the company. Domestic institutions moved −0.8 points over the same window, to 14.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +1.0 points over 8 quarters to 4.3%; Domestic institutions: −0.8 points over 8 quarters to 14.5%; Promoters: −0.1 points over 8 quarters to 27.1%.

Why the register moved: foreign institutions drove it (+1.0 points), absorbed on the other side by domestic institutions (−0.8 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Krsnaa Diagnostics Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions